Institutional members access full text with Ovid®

Share this article on:

Interleukin 1β Blockade Improves Signs and Symptoms of Chronic Calcium Pyrophosphate Crystal Arthritis Resistant to Treatment

Diamantopoulos, Andreas P. MD*†; Brodin, Christer MD*; Hetland, Helene MD*; Haugeberg, Glenn MD*†

JCR: Journal of Clinical Rheumatology: September 2012 - Volume 18 - Issue 6 - p 310–311
doi: 10.1097/RHU.0b013e31826149a2
Case Reports

A 54-year-old woman with recurrent episodes of bilateral knee arthritis was admitted several times to the Department of Rheumatology. She was diagnosed to have chronic calcium pyrophosphate crystal arthritis. Interleukin 1β (IL-1β) plays a central role in the pathogenesis of inflammation induced by calcium pyrophosphate crystals, and IL-1β blockade may be an effective treatment in patients with severe chronic calcium pyrophosphate crystal arthritis. Because of the short effect of treatment with corticosteroids and the frequent attacks of arthritis, the patient was treated with the IL-1 receptor antagonist anakinra. She responded well after 1 week with normalization of inflammation. Eight months after the initiation of treatment, the patient has had no relapses, although we were unable to withdraw the anakinra.

From the *Department of Rheumatology, Hospital of Southern Norway, Kristiansand; and †Department of Neurosciences, Norwegian University of Science and Technology, Trondheim, Norway.

The authors declare no conflict of interest.

Correspondence: Andreas P. Diamantopoulos, MD, Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Service Box 416, 4604 Kristiansand, Norway. E-mail:

© 2012 Lippincott Williams & Wilkins, Inc.